http://nexavar.legalview.com/msn/ 2012-02-23 http://nexavar.legalview.com/msn/jennerex-appoints-lara-longpre-to-chief-operating-officer/1233424/ 2012-02-23 http://nexavar.legalview.com/msn/extracerebral-metastases-determine-the-outcome-of-patients-with-brain/1233423/ 2012-02-23 http://nexavar.legalview.com/msn/aveo-pharmaceuticals-inc-to-present-at-several-upcoming-investment-con/1233422/ 2012-02-23 http://nexavar.legalview.com/msn/the-cancer-chronicles-a-re-cap-from-last-year-i-hope-it-may-help-someo/1233421/ 2012-02-23 http://nexavar.legalview.com/msn/pipeline-review-bristol-myers-squibbs-5-keys-to-success/1233420/ 2012-02-23 http://nexavar.legalview.com/msn/cocktails-are-next-for-cancer-drug-makers/1233419/ 2012-02-23 http://nexavar.legalview.com/msn/penn-study-makes-breakthrough-in-shrinking-tumors-of-terminal-melanoma/1233418/ 2012-02-23 http://nexavar.legalview.com/msn/owing-to-increased-access-to-medical-care-and-a-growing-drug-treated-p/1233417/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pockets-59m-upfront-from-japanese-partner-to-market-myeloma-drugs/1233416/ 2012-02-23 http://nexavar.legalview.com/msn/aveo-pharma-stock-jumps-40-percent-in-a-week-ceo-notes-progress-in-piv/1233415/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-snags-339m-japan-deal-for-phiii-cancer-med/1233414/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-to-present-at-the-morgan-stanley-global-healthcar/1233413/ 2012-02-23 http://nexavar.legalview.com/msn/the-daily-scan/1195427/ 2012-02-23 http://nexavar.legalview.com/msn/thyroid-cancer-1st-treatment-in-30-years/1195426/ 2012-02-23 http://nexavar.legalview.com/msn/hope-for-melbourne-liver-cancer-patients/1195425/ 2012-02-23 http://nexavar.legalview.com/msn/combination-of-sir-spheres-and-sorafenib-confers-survival-benefit-for/1195424/ 2012-02-23 http://nexavar.legalview.com/msn/study-reveals-survival-benefit-for-patients-with-inoperable-hepatocell/1195423/ 2012-02-23 http://nexavar.legalview.com/msn/study-combo-melanoma-therapy-ineffective/1195422/ 2012-02-23 http://nexavar.legalview.com/msn/cancer-treatment-pioneered-in-melbourne-being-hailed-as-a-global-lifes/1195421/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-to-participate-in-goldman-sachs-2010-healthcare-c/1195420/ 2012-02-23 http://nexavar.legalview.com/msn/arqules-sky-high-but-there-still-could-be-upside/1195419/ 2012-02-23 http://nexavar.legalview.com/msn/aveo-pharma-aveo-presents-data-on-tivozanib-at-asco/1195418/ 2012-02-23 http://nexavar.legalview.com/msn/human-genome-sciences-announces-results-of-randomized-phase-2-trial-of/1195417/ 2012-02-23 http://nexavar.legalview.com/msn/hgs-trial-showed-no-difference-in-disease-response/1195416/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-announces-carfilzomib-data-presentations-at-the-1/1195415/ 2012-02-23 http://nexavar.legalview.com/msn/cash-delay-for-cancer-treatment-could-cost-16000-lives/1195414/ 2012-02-23 http://nexavar.legalview.com/msn/clinical-outcome-in-metastatic-renal-cell-carcinoma/1157695/ 2012-02-23 http://nexavar.legalview.com/msn/ardea-biosciences-rdea594-preliminary-phase-2b-results/1157694/ 2012-02-23 http://nexavar.legalview.com/msn/lessons-of-a-618616-death/1157693/ 2012-02-23 http://nexavar.legalview.com/msn/arqule-inc-q3-2009-earnings-call-transcript/1130958/ 2012-02-23 http://nexavar.legalview.com/msn/sorafenib-targets-acute-myeloid-leukemia-driven-by-mutant-flt3-gene/1130957/ 2012-02-23 http://nexavar.legalview.com/msn/treatment-with-rad001-increases-time-without-tumour-growth-in-patients/1130956/ 2012-02-23 http://nexavar.legalview.com/msn/bay-biz-buzz-intel-faces-ny-anti-trust-suit/1130955/ 2012-02-23 http://nexavar.legalview.com/msn/bay-biz-buzz-cisco-profit-better-than-expected/1130954/ 2012-02-23 http://nexavar.legalview.com/msn/cost-effectiveness-of-sorafenib-for-second-line-treatment-of-advanced/1130953/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-inc-reports-operating-results-10-q/1130952/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-to-present-at-the-credit-suisse-18th-annual/1130951/ 2012-02-23 http://nexavar.legalview.com/msn/2-takeover-targets-in-the-pharma-market/1130950/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharmaceuticals-reports-third-quarter-2009-financial-results/1130949/ 2012-02-23 http://nexavar.legalview.com/msn/ardea-biosciences-initiates-phase-2b-clinical-trial-of-rdea594-lead/1106790/ 2012-02-23 http://nexavar.legalview.com/msn/bayer-says-uk-cost-agency-delays-ruling-on-nexavar/1106789/ 2012-02-23 http://nexavar.legalview.com/msn/unusual-11-mid-day-movers-722-meg-somx-onxx-orex-higher-heb-ati/1106788/ 2012-02-23 http://nexavar.legalview.com/msn/efficacy-of-sorafenib-on-metastatic-renal-cell-carcinoma-in-asian/1106787/ 2012-02-23 http://nexavar.legalview.com/msn/novel-therapeutics-for-melanoma/1106786/ 2012-02-23 http://nexavar.legalview.com/msn/do-doctor-politicians-have-an-advantage-in-the-health-care-debate/1106785/ 2012-02-23 http://nexavar.legalview.com/msn/older-cancer-patients-have-more-frailty-than-other-seniors/1106784/ 2012-02-23 http://nexavar.legalview.com/msn/investigating-role-of-brain-tumors-in-deafness/1106783/ 2012-02-23 http://nexavar.legalview.com/msn/afinitor-approved-in-eu-as-first-treatment-proven-to-benefit/1106782/ 2012-02-23 http://nexavar.legalview.com/msn/afinitor-approved-for-advanced-kidney-cancer/1106781/ 2012-02-23 http://nexavar.legalview.com/msn/potential-cant-buy-me-love/1106780/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-2q-profit-doubles-on-nexavar-sales/1106779/ 2012-02-23 http://nexavar.legalview.com/msn/the-wrong-way-to-invest-in-the-right-stocks/1106778/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-offering-322-million-in-stock-notes/1106777/ 2012-02-23 http://nexavar.legalview.com/msn/virginia-reclaims-1-spot/1106776/ 2012-02-23 http://nexavar.legalview.com/msn/pharmas-market-video/1106775/ 2012-02-23 http://nexavar.legalview.com/msn/fda-oks-new-kidney-cancer-drug/1106774/ 2012-02-23 http://nexavar.legalview.com/msn/scientists-learn-how-cancer-drugs-cause-hypertension/1106773/ 2012-02-23 http://nexavar.legalview.com/msn/cancer-lottery-london-patients-get-three-times-more-funding-than/1106772/ 2012-02-23 http://nexavar.legalview.com/msn/onyx-pharma-slides-after-analyst-lowers-rating/1106771/ 2012-02-23